2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-129666
    NSC-65847 6949-15-1 98%
    NSC-65847 is a groundbreaking dual inhibitor targeting both viral neuraminidase and Streptococcus pneumoniae neuraminidase.
    NSC-65847
  • HY-129682
    LY125180 74515-39-2 98%
    LY125180 is a serotonin uptake inhibitor. LY125180 competitively inhibits the uptake of serotonin and norepinephrine by cortical synaptosomes and of dopamine by striatal synaptosomes, with Ki values of 0.06 μM, 2.2 μM and 2.5 μM respectively.
    LY125180
  • HY-129688
    Sut-8701 123577-73-1 98%
    Sut-8701 is a Cholecystokinin (HY-P2932) analog that effectively slows the degenerative process of Alzheimer's disease by protecting the integrity of cholinergic neurons in the nucleus basalis.
    Sut-8701
  • HY-12980A
    Batefenterol Succinate 945905-37-3 98%
    Batefenterol Succinate (GSK961081 Succinate) is a first-of-its-kind inhaled bifunctional bronchodilator with smooth muscle relaxant properties. The activities of Batefenterol Succinate include acting as a smooth muscle parasympathetic antagonist and a beta2-adrenoceptor agonist. Batefenterol Succinate is used to improve respiratory function, especially in patients with chronic obstructive pulmonary disease (COPD).
    Batefenterol Succinate
  • HY-129810
    PD 135158 130325-35-8 98%
    PD 135158 (CAM 1028) is a selective CCKB receptor antagonist with an IC50 of 2.8 nM against mouse cortex CCKB. PD 135158 shows anxiolytic activity.
    PD 135158
  • HY-129822
    5-EAPB hydrochloride 1823776-22-2 98%
    5-EAPB hydrochloride is a benzofuran.
    5-EAPB hydrochloride
  • HY-129824
    3-Methyl orsellinic acid 4707-46-4
    3-Methyl orsellinic acid is the fungal metabolite. 3-Methyl orsellinic acid can be used for synthesis of tripodalsporormielones AeC, and exhibits potential in researches related to memory and cognition.
    3-Methyl orsellinic acid
  • HY-129850
    4-Chloromethamphetamine hydrochloride 30572-91-9 98%
    4-Chloromethamphetamine hydrochloride is a new psychoactive substance belonging to the amphetamine class.
    4-Chloromethamphetamine hydrochloride
  • HY-129862
    Eclanamine maleate 67450-45-7 98%
    Eclanamine maleate is functionally categorized as a nontricyclic antidepressant.
    Eclanamine maleate
  • HY-129876
    D-NAME hydrochloride 50912-92-0 98%
    D-NAME (D-NG-nitroarginine methyl ester) hydrochloride is a potent nitric oxide synthase (NOS) inhibitor. D-NAME hydrochloride inhibits the activity of NOS, reducing the production of nitric oxide.
    D-NAME hydrochloride
  • HY-12987R
    Pimozide (Standard) 2062-78-4
    Pimozide (Standard) is the analytical standard of Pimozide. This product is intended for research and analytical applications. Pimozide is a dopamine receptor antagonist, with Kis of 1.4 nM, 2.5 nM and 588 nM for dopamine D2, D3 and D1 receptors, respectively, and also has affinity at α1-adrenoceptor, with a Ki of 39 nM; Pimozide also inhibits STAT3 and STAT5.
    Pimozide (Standard)
  • HY-129907
    2-AEMP 321882-95-5 98%
    2-AEMP (2-Aminoethyl methylphosphonate) is an anti-GABA(A)-ρ1 receptor compound with antagonist activity. 2-AEMP exhibits competitive inhibition compared to TPMPA with an IC(50) value of 18 μM, compared to 7 μM for TPMPA. The release rate of inhibition at termination of 2-AEMP is significantly higher than that of TPMPA. The preincubation time required for the onset of inhibition of 2-AEMP is much shorter than that of TPMPA. Some analogs of 2-AEMP, especially those with benzyl or n-butyl substituents, show lower potency in terms of biological activity.
    2-AEMP
  • HY-129923
    (R)-Omeprazole sodium 161796-77-6 98%
    (R)-Omeprazole sodium is a gastric acid resistant compound with activity to inhibit gastric acid secretion. (R)-Omeprazole sodium is metabolized in vivo, and its metabolism is primarily affected by cytochrome P450 enzymes. The interaction between (R)-Omeprazole sodium and mannitol may affect its bioavailability in formulations. (R)-Omeprazole sodium exhibits reversible direct and metabolism-dependent inhibition of CYP2C19.
    (R)-Omeprazole sodium
  • HY-129947
    (-)-Carveol 1253216-40-8 98%
    (-)-Carveol is a natural unsaturated monocyclic monoterpene alcohol with the activity of regulating neural excitability. (-)-Carveol can activate or inhibit neural excitability by changing its chemical structure, which has potential significance for the design of targeted compounds. (-)-Carveol can also be used as a fragrance in cosmetics and a flavor additive in the food industry.
    (-)-Carveol
  • HY-129954
    6-EAPB hydrochloride 1823318-37-1 98%
    6-EAPB hydrochloride is a benzofuran.
    6-EAPB hydrochloride
  • HY-129980
    NPC-15437 dihydrochloride 141774-20-1 98%
    NPC-15437 dihydrochloride is a selective, penetrable and reversible protein kinase C (PKC) inhibitor, with an IC50 of 19 μM. NPC-15437 dihydrochloride interferes with mechanisms underlying memory consolidation.
    NPC-15437 dihydrochloride
  • HY-129985
    Clovoxamine 54739-19-4 98%
    Clovoxamine (DU23811) (Compound 35) has binding affinity for serotonin transporter (SERT) (Ki: 61 nM). Clovoxamine is a 5-HT and norepinephrine reuptake (NE) re-uptake inhibitor. Clovoxamine is an antidepressant.
    Clovoxamine
  • HY-130011
    CCG-232964 2349373-70-0 98%
    CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF. CCG-232964 inhibits LPA-induced CTGF gene expression.
    CCG-232964
  • HY-130070
    QO-40 1259536-70-3 98.77%
    QO-40, a pyrazolo[1,5-a]pyrimidine-7(4H)-one (PPO) derivative, is a KCNQ2/KCNQ3 K+ channels activator with an EC50 of 6.94 μM. QO-40 stimulated Ca2+-activated K+ current (IK(Ca)) with an EC50 value of 2.3 μM in pituitary GH3 lactotrophs.
    QO-40
  • HY-130176
    UFP-512 480446-44-4 98%
    UFP-512 is a selective and potent σ-opioid receptor (DOP receptor) peptidic agonist with antidepressant- and anxiolytic-like effects. UFP-512 exhibits as a potent agonist on adenylyl cyclase inhibition and Erk1/2 activation. UFP-512 induces phosphorylation of DOP receptors on Ser363 with a low desensitization of the cAMP pathway. UFP-512 is promising for research of mood disorders.
    UFP-512
Cat. No. Product Name / Synonyms Application Reactivity